Crescendo Bioscience Announces Four Studies with Vectra® DA Will Be Featured at the 2018 European League Against Rheumatism Annual Meeting

SALT LAKE CITY, June 06, 2018 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that data on the use of the Vectra^® DA test will be presented at the European League Against Rheumatism (EULAR) annual meeting being held June 13-16, 2018, in Amsterdam.  Vectra DA is the only multi-biomarker blood test proven to predict radiographic progression in patients with rheumatoid arthritis (RA).

“We are excited to see our academic collaborators presenting studies with Vectra DA at EULAR. The emerging data further advances knowledge of biomarker testing and its role in addressing the needs of patients with RA," said Elena Hitraya, M.D., Ph.D., chief medical officer, Crescendo Bioscience.  “The information provided by the Vectra DA test gives physicians objective information to assist in treatment decisions for their patients.”

Follow Vectra DA on Twitter via @VectraDA and Myriad via @MyriadGenetics to stay informed about symposium news and updates by using the hashtag #EULAR2018. For more information, including a complete list of abstracts and presentations, please visit the EULAR website at http://www.congress.eular.org/.

About Vectra^® DA
Vectra DA is the only validated multi-biomarker molecular blood test that simultaneously measures 12 key biomarkers to provide an objective and personalized measure of rheumatoid arthritis (RA) disease activity. Vectra DA is the best test at predicting radiographic progression and provides scores range from 1 to 100 to categorize RA disease activity into low, moderate or high to guide medical management.  For more information, please visit: www.vectra-da.com.

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on three strategic imperatives:  transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com

Myriad, the Myriad logo, BART, BRACAnalysis, COLARIS, COLARIS AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.      

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Vectra DA data to be presented at the 2018 European League Against Rheumatism (EULAR) Annual Meeting, June 13-16, 2018 in Amsterdam; the potential clinical utility of the Vectra DA study results and findings for guiding treatment decisions in patients with RA; and the Company's strategic directives under the captions "About Crescendo Bioscience" and "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2017, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.  All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.